Submitted by endpointsnews6292 in business
Moderna has inked a deal worth up to $1.8 billion with TCR specialist Immatics that broadens the company’s position in mRNA-based cancer research. The Cambridge, MA-based mRNA giant has promised Immatics $120 million upfront and more than $1.7 billion in deve…